To be, or not to be … What determines the destruction of a protein in response to metabolic cues? In the current issue of JBC, Wangeline and Hampton shed new light on this existential question by studying the classic case of HMGCR (Hmg2 in yeast), the rate-limiting step in sterol synthesis, and find a metabolic cue that causes "allosteric misfolding" and subsequent destruction of the protein, a concept they name mallostery.
To be, or not to be … What determines the destruction of a protein in response to metabolic cues? In the current issue of JBC, Wangeline and Hampton shed new light on this existential question by studying the classic case of HMGCR (Hmg2 in yeast), the rate-limiting step in sterol synthesis, and find a metabolic cue that causes "allosteric misfolding" and subsequent destruction of the protein, a concept they name mallostery.
Making a protein is a markedly different proposition from making a pretzel. And yet, if either is misfolded through the production process, the defective product will not pass quality control and will be picked out for prompt disposal. Indeed, the synthesis of proteins in the endoplasmic reticulum (ER) 2 is tightly coupled with the disposal of misfolded proteins by the ubiquitin-proteasomal system. But, how are proteins regulated after they've passed this initial checkpoint? Metabolic regulation also requires tight control of the protein levels of key enzymes in response to changing physiological circumstances, and thus also requires disposal by systems like the proteasome (1) . So, can protein quality control be co-opted for metabolic regulation?
One of the best studied examples where quality and metabolic control overlap is 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) (2), best known as the target of the highly successful statin class of cholesterol-lowering drugs. HMGCR, found in the ER in both human and yeast, catalyzes the conversion of mevalonate to HMG-CoA as the rate-limiting step in the production of both isoprenoids and sterols (ergosterol in yeast and cholesterol in higher eukaryotes).
Over the past four decades, seminal studies (including Refs. 3 to 6) in both mammalian and fungal systems from many groups have provided a detailed picture of the ER-associated degradation of HMGCR, which is regulated by sterol and isoprenoid signals. The 20-carbon isoprenoid geranylgeranyl pyrophosphate (GGPP) features in the proteasomal degradation of both mammalian HMGCR and Hmg2, one of two HMGCR enzymes in Saccharomyces cerevisiae. However, there are differences: While GGPP is the primary signal in the degradation of Hmg2 (7) , it merely enhances the sterol-mediated degradation of mammalian HMGCR (5) . However, the specific mechanism by which GGPP triggers Hmg2 degradation has not been clear.
Here, Wangeline and Hampton (8) show just how exquisitely sensitive Hmg2 degradation is to GGPP and elucidate a mechanism for GGPP function, which is reminiscent of allostery. Typically, allosteric regulators target enzymes potently, specifically, and reversibly by binding to sites other than the active site. These allosteric ligands can then trigger conformational changes that create novel binding sites on the enzyme, which often exists as a multimer. In a similar vein, Wangeline and Hampton (8) demonstrate that GGPP is a specific, potent, and reversible ligand that induces a conformational change in the membrane-bound portion of Hmg2 missing the active site. However, unlike in existing examples of allostery, this change does not activate or inhibit the enzyme but instead destroys it by causing the misfolding and malformation of Hmg2, so that it is disposed of by constitutive quality control processes ( Fig. 1 ). Hence, they call this mechanism "allosteric misfolding" or "mallostery."
Wangeline and Hampton (8) carefully construct a compelling case by employing two main tools to investigate the phenomenon of GGPP-mediated degradation of Hmg2. For experiments in yeast cells, they utilized a version of Hmg2 lacking the catalytic domain and fused this to GFP for routine flow cytometry analyses of degradation rates. For in vitro experiments, the same construct was used, but an additional Myc epitope tag was inserted into a loop on the inside of the ER membrane, enabling limited proteolysis experiments in microsome preparations, a classic way to investigate conformational changes in a protein.
They determined that GGPP is highly specific for stimulating degradation of WT, but not mutant forms of Hmg2 that are not regulated by this pathway. Moreover, degradation does not occur with other structurally similar isoprenoids. What was especially striking was the incredible potency of GGPP, with as little as 15 nM being capable of affecting the in vitro proteolysis assay. What this low, physiologically relevant concentration and structural specificity of GGPP toward WT Hmg2 tell us is that we are unlikely to be dealing with a general effect of GGPP on the ER membrane structure, but rather a specific ligand for Hmg2.
Not only was GGPP potent and specific, but the effect was reversible, as washing of the microsomes stabilized the Hmg2
The authors declare that they have no conflicts of interest with the contents of this article. 1 population. GGPP's effect could also be reversed in vitro and in yeast cells through the addition of a chemically similar analog, GGSPP, which has a sulfur atom replacing the more electronegative oxygen. The authors provide two lines of evidence in support of GGPP-mediated unfolding of Hmg2. Firstly, chemical chaperones including glycerol, betaine, and proline extended the halflife of Hmg2 in cells despite GGPP addition. And secondly, the same chaperones opposed the structural changes induced by GGPP when tested with the in vitro proteolysis assay.
The authors also confirmed that Hmg2, like other allosterically regulated proteins, exists as a multimer using co-immunoprecipitation experiments of two differently epitope-tagged Hmg2 constructs, with no change in the multimerization state being observed when GGPP was added.
So, GGPP emerges as the first reported mallosteric regulator (Fig. 1) . Currently, this specific mallosteric mechanism is restricted to yeast, because GGPP's role in enhancing degradation of mammalian HMGCR appears quite distinct, involving GGPP sensing in ER membranes by UBIAD1, a prenyltransferase required for vitamin K2 formation. In mammals, elevated sterols increase ubiquitination of HMGCR, but it remains tethered to the ER still bound to UBIAD1. Increased GGPP levels cause UBIAD1 to dissociate from the ubiquitinated reductase, allowing its extraction from the membrane and degradation in the cytosol (2) .
With the discovery of this new mechanism, a host of additional questions emerges. For example, it seems likely that Hmg2 possesses a high affinity binding site for the potent GGPP, but where? What exactly does GGPP unfold in Hmg2 that pushes it into the protein quality control machinery? The transition of a locally structured region into an exposed misfolded hydrophobic patch is one possibility. It is also fascinating that ergosterol, the end-product of the pathway, does not influence Hmg2 degradation. Why is it that Hmg2 only has a strong response to an isoprenoid intermediate and not the end-product? It may well be because evolving from a single cell organism to multicellularity demands greater sophistication in feedback regulation, requiring a richer repertoire of both intermediate and end-product signals.
We can expect more examples of this useful concept of mallostery to emerge from the hazy zone between quality and met-abolic control. For instance, downstream enzymes in sterol synthesis also undergo regulated proteosomal degradation (9, 10) , and these may also involve mallostery. The scene is also set for the development of small molecules that may mimic or inhibit mallostery for clinical applications. And so, we look forward to sitting back and enjoying the next installment: Mallostery: The Sequel (The story unfolds), perhaps disposing of a pretzel or two. Figure 1 . Proposed model of GGPP-mediated degradation of Hmg2 through "allosteric misfolding" or "mallostery." The model revolves around the idea that local misfolding induced by the potent isoprenoid GGPP sends out a distress signal so that Hmg2 can be degraded. Hmg2 exists as a multimer, which can exist in two different conformations, either the stable native state or the malformed state. Binding of GGPP induces structural changes in Hmg2, which exposes new sites (in green) that increase susceptibility to added proteases. The changes would then lead to degradation by the protein quality control. The chemically similar analog GGSPP can oppose the action of GGPP.
